← Leaderboards
K Lea Sewell
Beth Israel Deaconess Medical Center
$387,832
Attributed
$387,832
Total exposure
7
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$387,832 · 7
By mechanism
M01$387,832 · 7
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- George C Tsokos$40,494,511
- Susan L Greenspan$27,746,173
- Raghu Kalluri$29,360,132
- Anne Nicholson-Weller$3,512,328
- David Trentham$775,664
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationDrug Screening /EvaluationSystemic Lupus ErythematosusOligonucleotidesDrug Adverse EffectAntiantibodyConnective Tissue Disorder ChemotherapyRheumatoid ArthritisImmunotherapyDosageLongitudinal Human StudyMedical ComplicationMonoclonal AntibodyNephritisOral AdministrationSkeletal Disorder ChemotherapyAfrican AmericanDrug Administration Rate /DurationCd40 MoleculeGlomerulonephritisAntiarrhythmic AgentInterleukin 2
Grant awards (32)
BG9588 (ANTI CD40LAB)--SYSTEMIC LUPUS/GLOMERULONEPHRITIS$0
M01 · FY2002 · RR
OPEN LABEL LJP 394 FOR SLE W/ DNA AB$0
M01 · FY2002 · RR
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS$0
M01 · FY2002 · RR
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
ORAL COLLORAL IN ADULT PATIENTS W/ ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2002 · RR
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB$0
M01 · FY2002 · RR
BG9588 (ANTI CD40LAB)--SYSTEMIC LUPUS/GLOMERULONEPHRITIS$0
M01 · FY2001 · RR
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS$0
M01 · FY2001 · RR
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
ORAL COLLORAL IN ADULT PATIENTS W/ ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2001 · RR
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB$0
M01 · FY2001 · RR
OPEN LABEL LJP 394 FOR SLE W/ DNA AB$0
M01 · FY2001 · RR
DOSE RANGING TRIAL OF LJP 394 IN PATIENTS W/ SLE$193,916
M01 · FY2000 · RR
DOSE RANGING TRIAL OF LJP 394 IN PATIENTS W/ SLE$193,916
M01 · FY2000 · RR
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS$0
M01 · FY2000 · RR
BG9588 (ANTI CD40LAB)--SYSTEMIC LUPUS/GLOMERULONEPHRITIS$0
M01 · FY2000 · RR
BG9588 (ANTI CD40LAB)--SYSTEMIC LUPUS/GLOMERULONEPHRITIS$0
M01 · FY2000 · RR
BG9588 (ANTI CD40LAB)--SYSTEMIC LUPUS/GLOMERULONEPHRITIS$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ DNA AB$0
M01 · FY2000 · RR
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS$0
M01 · FY2000 · RR
REPEATED DOSES OF LJP 394 IN PATIENTS WITH SLE NEPHRITIS$0
M01 · FY2000 · RR
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
LONG TERM USE OF DAB(389)IL 2 THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ORAL COLLORAL IN ADULT PATIENTS W/ ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ORAL COLLORAL IN ADULT PATIENTS W/ ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
ORAL COLLORAL IN ADULT PATIENTS W/ ACUTE RHEUMATOID ARTHRITIS$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ HIGH DNA AB$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ DNA AB$0
M01 · FY2000 · RR
OPEN LABEL LJP 394 FOR SLE W/ DNA AB$0
M01 · FY2000 · RR